Zacks Investment Research lowered shares of Omeros Corporation (NASDAQ:OMER) from a hold rating to a sell rating in a research report report published on Thursday morning.
According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
Several other research analysts also recently commented on the stock. Maxim Group set a $24.00 price target on shares of Omeros Corporation and gave the stock a buy rating in a research note on Friday, October 20th. Cantor Fitzgerald reaffirmed a hold rating and issued a $19.00 price target (up previously from $15.00) on shares of Omeros Corporation in a research note on Thursday, August 24th. Cowen and Company downgraded shares of Omeros Corporation from an outperform rating to a market perform rating in a research note on Thursday, November 2nd. Wedbush reaffirmed an outperform rating and issued a $47.00 price target on shares of Omeros Corporation in a research note on Friday, August 18th. Finally, HC Wainwright started coverage on shares of Omeros Corporation in a research note on Wednesday. They issued a buy rating and a $30.00 price target on the stock. Two research analysts have rated the stock with a sell rating, four have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $34.14.
Shares of Omeros Corporation (NASDAQ:OMER) traded up $4.08 on Thursday, hitting $18.17. 6,481,400 shares of the stock traded hands, compared to its average volume of 793,075. Omeros Corporation has a 1-year low of $8.71 and a 1-year high of $27.09. The company has a current ratio of 2.15, a quick ratio of 2.11 and a debt-to-equity ratio of -1.49.
Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million during the quarter, compared to analysts’ expectations of $17.82 million. The company’s quarterly revenue was up 91.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.34) EPS. equities research analysts predict that Omeros Corporation will post -1.32 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2017/11/11/omeros-corporation-omer-lowered-to-sell-at-zacks-investment-research.html.
Institutional investors have recently modified their holdings of the business. First Interstate Bank bought a new position in Omeros Corporation during the 3rd quarter worth about $108,000. Legal & General Group Plc grew its holdings in Omeros Corporation by 7.8% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 751 shares in the last quarter. Hanseatic Management Services Inc. grew its holdings in Omeros Corporation by 10,919.6% during the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 10,592 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in Omeros Corporation during the 3rd quarter worth about $256,000. Finally, SG Americas Securities LLC grew its holdings in Omeros Corporation by 138.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 7,067 shares in the last quarter. Institutional investors own 44.97% of the company’s stock.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.